Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 21/12/2016 Signatope GmbH’s founding team (from left to right) Prof. Dr. Hugo Hämmerle, Dr. Oliver Pötz, Dr. Hannes Planatscher, Dr. Octavian Schatz and Dr. Thomas Joos.

    For all types of tests: Signatope’s biomarker assays

    Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.

    https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
  • Press release - 13/12/2016 A laboratory device being loaded with small reaction vessels.

    Early-diagnosis systems from Baden-Württemberg help prevent the spread of drug-resistant pathogens

    More and more bacteria are developing resistance to multiple antimicrobial drugs. These multidrug-resistant bacteria can impede the action of common antibiotics via mutations or DNA transfer. More than 30,000 people are infected every year with multidrug-resistant bacteria in German hospitals alone. This could be prevented with appropriate hygiene measures and innovative test systems. Innovative test systems that enable reliable and rapid…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fruehdiagnostik-aus-baden-wuerttemberg-hilft-resistente-erreger-zu-stoppen
  • Article - 08/11/2016 Eine Hand mit Pipette führt die Farbreaktion in zwei Reaktionsgefäßen durch: Im ersten Gefäß ist der Reaktionsansatz noch farblos, im zweiten rot gefärbt.

    Towards at-home genetic testing

    The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Chemists at the University of Konstanz have now developed a genetic test that does not need to be carried out in the laboratory and can be evaluated with the naked eye, similar to a pregnancy test. The test would therefore be…

    https://www.gesundheitsindustrie-bw.de/en/article/news/towards-at-home-genetic-testing
  • Article - 05/09/2016 Glioblastom_MRT.jpg

    Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 02/08/2016 Huntington_Eiweiss_Abb_Dr_Katrin_Lindenberg_Neurologie_UK_Ulm.jpg

    Can the ticking Huntington clock be stopped?

    An early phase clinical study involving thirty-six Huntington’s disease (HD) patients is currently underway to investigate whether a method called gene silencing can cure the disease. If the gene that causes the disease can be turned off, it would be the first step towards a treatment that not only fights symptoms but actually treats the causes of HD, hence providing a cure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/can-the-ticking-huntington-clock-be-stopped
  • Company profile - 25/07/2016 300microns-3D-Zellaggregate.jpg

    300MICRONS: 3D cell culture solutions tailored to customer needs

    What happens in tissues and organs and how do they react to pharmaceutical substances? Three-dimensional cell cultures can reproduce reality far better than a single-cell layer can. With good reason. Reality is far from two-dimensional. A company called 300MICRONS GmbH develops films with tiny indentations that provide optimal conditions for cells to grow into 3D cell aggregates.

    https://www.gesundheitsindustrie-bw.de/en/article/news/300microns-3d-cell-culture-solutions-tailored-to-customer-needs
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Company profile - 14/07/2016 Schematic showing how the neurostimulator leads to the stimulation of the vagus nerve lowers the blood pressure.

    neuroloop GmbH: how the manipulation of neuronal information can lower blood pressure

    Millions of people worldwide suffer from high blood pressure. However, taking medicines to control high blood pressure does not work for everyone. Dr. Dennis Plachta and Prof. Dr. Thomas Stieglitz from IMTEK have now developed a neurostimulator to control blood pressure. Together with Dr. Michael Lauk, an experienced company founder, the two researchers set up a company called neuroloop, which is funded by Aesculap AG and aims to turn the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/neuroloop-gmbh-how-the-manipulation-of-neuronal-information-can-lower-blood-pressure
  • BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016 Biolag_Biopro_Workshop1.jpg

    DiagNeeds: translating clinical requirements into new products

    (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
  • Company profile - 05/07/2016 Logo_final.jpg

    HS-Analysis GmbH – using digital histology to develop new drugs

    The idea of analysing tissue samples automatically sounds more of a pipe dream than anything else. However, it already happens. HS-Analysis GmbH's ability to interpret tissue samples automatically is driving new drug development a decisive step forward.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hs-analysis-gmbh-using-digital-histology-to-develop-new-drugs
  • Article - 30/05/2016 The photo shows a next-generation sequencer consisting of a sequencing unit and a desktop computer.

    The unknown dark spot of the microcosm

    The world of microorganisms is still largely unknown. Researchers such as Kai Sohn from the Fraunhofer IGB in Stuttgart are working on decoding, analysing and gradually gaining a better understanding of the microbial genome. In their search for new enzymes and other biomolecules, both biotechnologists and pharmacologists are interested in micoorganisms, and physicians are hoping that detailed insights into the microbial genome will lead to the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-unknown-dark-spot-of-the-microcosm
  • Article - 09/05/2016 The schematic on the left shows the concept: an implantable single-use probe head, coupled to a telemetry unit close to the patient's bed by way of a plug and a cord. The telemetry unit is shown as a small rectangular box from which enables wireless transfer of the recorded data to the hospital computer network. The schematic on the right shows details of the plug connection.

    FlexiTel – microsensors for tissue monitoring

    When soft tissue is transplanted, for example in a patient undergoing tumour surgery, care must be taken to ensure that the new tissue is connected to the blood system in the area where the tumour has been removed. How well this works is difficult to find out, especially in the case of deep-seated defects. Partially implantable microsensor probes called FlexiTel have the potential to improve this situation by monitoring success during the first…

    https://www.gesundheitsindustrie-bw.de/en/article/news/flexitel-microsensors-for-tissue-monitoring
  • Article - 02/05/2016 Schematic showing immune cells recognise a hepatitis C virus.

    Hepatitis C: a new starting point for vaccine development

    With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
  • Article - 04/04/2016 Microscope image showing how cells that have taken up fluorescein glow when exposed to UV light.

    An intelligent system for the storage and controlled release of pharmaceutical substances

    A sophisticated reservoir that sits under the skin and dispenses precise quantities of drugs locally and at a particular point in time now exists. A junior research group from the University of Freiburg’s BrainLinks-BrainTools excellence cluster led by Dr. Maria Asplund and her doctoral student Christian Böhler from the Department of Microsystems Engineering (IMTEK) has developed a small storage system made of organic-inorganic hybrid material…

    https://www.gesundheitsindustrie-bw.de/en/article/news/an-intelligent-system-for-the-storage-and-controlled-release-of-pharmaceutical-substances
  • Article - 21/03/2016 Schematic presentation before and after treatment showing the effect of the therapy. Blood vessel density improves considerably.

    Shock wave therapy gives hope to many men

    Although the approval of vasodilatory drugs made available an effective medicine for treating erectile dysfunction, not all men respond to this type of treatment. MTS Medical UG from Konstanz has developed a therapeutic device that means that these men can now get help too. What's more, the device has no adverse health effects.

    https://www.gesundheitsindustrie-bw.de/en/article/news/shock-wave-therapy-gives-hope-to-many-men
  • Article - 03/03/2016 Schematic showing how liquid biopsies can be used to analyse freely circulating (fc) DNA in the blood. The schematic shows the technique as applied to GIST (gastrointestinal stroma tumours).

    Liquid biopsies – beacons of hope for cancer diagnosis?

    Researchers around the world, including researchers from the Freiburg University Medical Center, are working on developing simple blood tests, so-called liquid biopsies, that can be used to obtain accurate information about tumour staging and the progress of therapy. An international liquid biopsy symposium was held in Freiburg in October 2015 and has produced valuable insights.

    https://www.gesundheitsindustrie-bw.de/en/article/news/liquid-biopsies-beacons-of-hope-for-cancer-diagnosis
  • Article - 25/01/2016 overview.png

    And yet another biological from Biberach

    Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. We spoke with Dr. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. Her research focuses on thrombosis, haemostasis and coagulation. She is involved in the scientific monitoring of dabigatran (Pradaxa), an oral anticoagulant that, in 2008,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
  • Article - 21/01/2016 The photo shows a man evaluating a technological work step.

    Genome research as information research

    DNA sequencing has become indispensable in modern science. Innovative advances that will bring about changes in the life sciences and medicine are due to rapid developments in genome analysis technologies. In the interview below, Peter Pohl, CEO and co-founder of GATC Biotech AG, explains why DNA sequencing will become even more important in future.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genome-research-as-information-research
  • Article - 18/01/2016 The photo shows two blister packs with tablets.

    New approaches in the life sciences industry: innovative strategies for courageous companies

    For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
  • Article - 21/12/2015 Computer model of the heart shown in different colours.

    Using a heart simulator for optimal therapy

    A realistic computer model of the human heart is expected to make treating heart diseases more effective: doctors will be able to test medicines and surgical techniques on the computer heart and determine the most effective therapy. Olaf Dössel, director of the Institute of Biomedical Engineering at the Karlsruhe Institute of Technology, believes that his team's heart model is among the top five in the world.

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-a-heart-simulator-for-optimal-therapy
  • Article - 14/12/2015 Fluorescence microscope image showing the degradation of the proteins.

    Cathepsin L: overcoming stress in tumours

    Cathepsins are proteases, i.e. enzymes that break down proteins into smaller fragments. They are also involved in the formation of new blood vessels and wound healing. Another thing that cathepsins do is help tumours spread and form metastases in the body. Prof. Dr. Thomas Reinheckel and his team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg are studying how this happens. Insights into the role of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cathepsin-l-den-stress-im-tumor-ueberwinden
  • Article - 07/12/2015 Fluorescence image where plaques are clearly visible.

    Microglial cells – the health police of Alzheimer’s

    It starts with memory loss and disorientation. Alzheimer’s disease is the most common type of dementia and is characterised by the loss of neurons and synapses in the brain resulting from the aggregation of beta amyloid protein fragments into fibrils and plaques. Prof. Dr. Knut Biber and his team from the Division of Molecular Psychiatry at Freiburg University Medical Center have analysed these plaques in an in vivo-like cell culture system. They…

    https://www.gesundheitsindustrie-bw.de/en/article/news/microglial-cells-the-health-police-of-alzheimers
  • Article - 02/12/2015 Schematic representation of the fMEG measurement principle. Left: cross-section through the abdomen of a pregnant woman, showing the foetus; right: measurement unit with the sensors of the fMEG shell. 
The light blue lines running from the belly of the pregnant woman to the right-hand side symbolise the magnetic waves that originate from the foetus and which are recorded.

    Diabetes research: can foetuses develop susceptibility to diabetes in uteri?

    The measurement of blood glucose levels reveals changes in foetal brain response after a pregnant woman has consumed glucose. The postprandial brain response generated by the unborn children of women with gestational diabetes differs from that of children of women without gestational diabetes. Researchers from Tübingen have been using magnetic encephalography to examine the effect of insulin on the brain and the relationships between gestational…

    https://www.gesundheitsindustrie-bw.de/en/article/news/diabetes-research-can-foetuses-develop-susceptibility-to-diabetes-in-uteri

Page 5 / 19

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 19
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search